Skip to main content

Advertisement

SpringerLink
Log in

Omission of axillary lymph node dissection for clinically node negative early-stage breast cancer patients

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

For clinically node negative (N0) breast cancer patients, sentinel node (SN) biopsy (SNB) is a standard technique and complete axillary lymph node dissection (ALND) remains the standard treatment when the SN is positive. However, the American College of Surgeons Oncology Group Z0011 trial and the International Breast Cancer Study Group 23-01 trial showed that SNB without ALND can offer excellent regional control and equal survival compared with ALND for limited macrometastatic and micrometastatic SN involvement, respectively. We retrospectively evaluated axillary control rates in clinically N0 patients who had no axillary surgical treatment.

Methods

Data on 158 patients who underwent breast-conserving therapy without any axillary surgical procedure between 1994 and 2010 were extracted. The last follow-up was on May 2013, and the overall median follow-up period was 119.0 months.

Results

Of all 158 patients, 10 (6.3 %) and 3 (1.9 %) developed locoregional and axillary recurrences, respectively. The 10-year locoregional and axillary recurrence rates were 5.8 and 2.1 %, respectively. The 5- and 10-year overall survival rates were 94.0 and 84.8 %, respectively. Cases with axillary recurrence tended to have common risk factors for recurrence.

Conclusion

Even if SNB and ALND were omitted, local and regional recurrence rates were very low among clinically N0 patients and were at the same levels shown in recent trials. This suggests that at least ALND might be safely avoided in clinically N0 patients without any obvious risk factors regardless of axillary nodal status after SNB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703–20.

    Article  PubMed  Google Scholar 

  2. Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595–600. doi:10.1097/SLA.0b013e3181c0e92a.

    Article  PubMed  Google Scholar 

  3. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546–53.

    Article  PubMed  Google Scholar 

  4. Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000;18:2553–9.

    CAS  PubMed  Google Scholar 

  5. Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27:2946–53. doi:10.1200/JCO.2008.19.5750.

    Article  PubMed  Google Scholar 

  6. Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004;240:462–8 discussion 468–471.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Kuerer HM, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007;110:723–30.

    Article  PubMed  Google Scholar 

  8. Pernas S, Gil M, Benítez A, Bajen MT, Climent F, Pla MJ, et al. Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence. Ann Surg Oncol. 2010;17:772–7.

    Article  PubMed  Google Scholar 

  9. Langer I, Guller U, Viehl CT, Moch H, Wight E, Harder F, et al. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Ann Surg Oncol. 2009;16:3366–74. doi:10.1245/s10434-009-0660-9.

    Article  PubMed  Google Scholar 

  10. Galimberti V, Botteri E, Chifu C, Gentilini O, Luini A, Intra M, et al. Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer? Breast Cancer Res Treat. 2012;131:819–25. doi:10.1007/s10549-011-1486-2.

    Article  PubMed  Google Scholar 

  11. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–33. doi:10.1016/S1470-2045(10)70207-2.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426–32. doi:10.1097/SLA.0b013e3181f08f32 discussion 432–433.

    PubMed  Google Scholar 

  13. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75. doi:10.1001/jama.2011.90.

    Article  CAS  PubMed  Google Scholar 

  14. Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297–305. doi:10.1016/S1470-2045(13)70035-4.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Sanuki N, Takeda A, Amemiya A, Ofuchi T, Ono M, Ogata H, Yamagami R, Hatayama J, Eriguchi T, Kunieda E. Outcomes of clinically node-negative breast cancer without axillary dissection: can preserved axilla be safely treated with radiation after a positive sentinel node biopsy? Clin Breast Cancer. 2013;13(1):69–76. doi:10.1016/j.clbc.2012.09.005.

    Article  PubMed  Google Scholar 

  16. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ, Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23. doi:10.1093/annonc/mdt303.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Posther KE, McCall LM, Blumencranz PW, Burak WE Jr, Beitsch PD, Hansen NM, et al. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. Ann Surg. 2005;242:593–9 discussion 599–602.

    PubMed Central  PubMed  Google Scholar 

  18. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8(10):881–8.

    Article  CAS  PubMed  Google Scholar 

  19. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006;106:4–16.

    Article  PubMed  Google Scholar 

  20. Wernicke AG, Goodman RL, Turner BC, Komarnicky LT, Curran WJ, Christos PJ, et al. A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance. Breast Cancer Res Treat. 2011;125:893–902. doi:10.1007/s10549-010-1167-6.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Reznik J, Cicchetti MG, Degaspe B, Fitzgerald TJ. Analysis of axillary coverage during tangential radiation therapy to the breast. Int J Radiat Oncol Biol Phys. 2005;61:163–8.

    Article  PubMed  Google Scholar 

  22. Wong JS, Taghian AG, Bellon JR, Keshaviah A, Smith BL, Winer EP, et al. Tangential radiotherapy without axillary surgery in early-stage breast cancer: results of a prospective trial. Int J Radiat Oncol Biol Phys. 2008;72:866–70. doi:10.1016/j.ijrobp.2008.01.031.

    Article  PubMed  Google Scholar 

  23. Takeda A, Shigematsu N, Kondo M, Amemiya A, Kawaguchi O, Sato M, Kutsuki S, Toya K, Ishibashi R, Kawase T, Tsukamoto N, Kubo A. The modified tangential irradiation technique for breast cancer: how to cover the entire axillary region. Int J Radiat Oncol Biol Phys. 2000;46(4):815–22.

    Article  CAS  PubMed  Google Scholar 

  24. Takeda A, Shigematsu N, Ikeda T, Kawaguchi O, Kutsuki S, Ishibashi R, Kunieda E, Takeda T, Takemasa K, Ito H, Uno T, Jinno H, Kubo A. Evaluation of novel modified tangential irradiation technique for breast cancer patients using dose-volume histograms. Int J Radiat Oncol Biol Phys. 2004;58(4):1280–8.

    Article  PubMed  Google Scholar 

  25. Ohashi T, Takeda A, Shigematsu N, Fukada J, Sanuki N, Amemiya A, et al. Dose distribution analysis of axillary lymph nodes for three-dimensional conformal radiotherapy with a field-in-field technique for breast cancer. Int J Radiat Oncol Biol Phys. 2009;73:80–7. doi:10.1016/j.ijrobp.2008.04.003.

    Article  PubMed  Google Scholar 

  26. Fujimoto N, Amemiya A, Kondo M, Takeda A, Shigematsu N. Treatment of breast carcinoma in patients with clinically negative axillary lymph nodes using radiotherapy versus axillary dissection. Cancer. 2004;101:2155–63.

    Article  PubMed  Google Scholar 

  27. Zurrida S, Orecchia R, Galimberti V, Luini A, Giannetti I, Ballardini B, et al. Axillary radiotherapy instead of axillary dissection: a randomized trial. Italian Oncological Senology Group. Ann Surg Oncol. 2002;9:156–60.

    Article  PubMed  Google Scholar 

  28. Hoebers FJ, Borger JH, Hart AA, Peterse JL, Th EJ, Lebesque JV. Primary axillary radiotherapy as axillary treatment in breast-conserving therapy for patients with breast carcinoma and clinically negative axillary lymph nodes. Cancer. 2000;88:1633–42.

    Article  CAS  PubMed  Google Scholar 

  29. Cabanes PA, Salmon RJ, Vilcoq JR, Durand JC, Fourquet A, Gautier C, et al. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. Lancet. 1992;339:1245–8.

    Article  CAS  PubMed  Google Scholar 

  30. Louis-Sylvestre C, Clough K, Asselain B, Vilcoq JR, Salmon RJ, Campana F, et al. Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. J Clin Oncol. 2004;22:97–101.

    Article  PubMed  Google Scholar 

  31. Furukawa T, Kubota T, Tanino H, Oura S, Yuasa S, Murate H, et al. Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay. Anticancer Res. 2000;20(5C):3657–8.

    CAS  PubMed  Google Scholar 

  32. Gentilini O, Veronesi U. Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). Breast. 2012;21(5):678–81. doi:10.1016/j.breast.2012.06.013.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Radiology, University of Tokyo Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan

    Reiko Kobayashi, Kenshiro Shiraishi, Kuni Ohtomo & Keiichi Nakagawa

  2. Department of Palliative Medicine, Research Hospital, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan

    Satoru Iwase

Authors
  1. Reiko Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenshiro Shiraishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Satoru Iwase
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kuni Ohtomo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keiichi Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenshiro Shiraishi.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kobayashi, R., Shiraishi, K., Iwase, S. et al. Omission of axillary lymph node dissection for clinically node negative early-stage breast cancer patients. Breast Cancer 22, 657–663 (2015). https://doi.org/10.1007/s12282-014-0532-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-014-0532-4

Keywords

Search

Navigation